Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction

Vascular 18F-FDG uptake marker represents inflammation in atherosclerotic lesions, but whether inflammation can be reversed by risk-modifying interventions has not, to our knowledge, been demonstrated. In this study, we evaluated the change of vascular 18F-FDG uptake in response to lifestyle intervention on serial PET/CT scans and further assessed how the findings relate to atherogenic risk reduction. METHODS: A total of 60 healthy adults underwent 18F-FDG PET/CT scans and atherogenic risk-factor assessment at baseline and again after 17.1 +/- 8.3 mo of practicing lifestyle modification. The PET/CT images were evaluated for the presence of vascular 18F-FDG lesions, and vessel-to-blood-pool 18F-FDG ratios were measured. Indices from summed ratios of positive lesions were compared and correlated to atherogenic risk factors. RESULTS: At follow-up, significant reductions in diastolic blood pressure (P < 0.05), total cholesterol (P < 0.05), and low-density lipoprotein level (P < 0.05) and an increase in high-density lipoprotein (HDL) level (P < 0.0001) were demonstrated. On the initial PET/CT scan, 50 of 60 subjects showed 1 or more 18F-FDG-positive lesions (5.9 +/- 5.0/subject), leading to a total of 352 vascular sites. On follow-up, 18F-FDG-positive lesions were significantly reduced to 2.1 +/- 2.2 sites per subject (P < 0.0001) and a total of 124 sites (64.8% reduction). Follow-up 18F-FDG-positive rates were significantly reduced for the aorta and iliac arteries. In addition, significant reductions in the whole-body 18F-FDG index from 1.39 +/- 1.23 to 0.53 +/- 0.59 (P < 0.0001) and carotid 18F-FDG index from 0.08 +/- 0.16 to 0.03 +/- 0.06 (P = 0.01) were shown. The whole-body 18F-FDG index correlated with total cholesterol (P < 0.05) and HDL level (P < 0.05), and the magnitude of reduction in the 18F-FDG index closely correlated to the amount of increase in plasma HDL level (P = 0.005). CONCLUSION: Our study demonstrated that vascular 18F-FDG uptake is reversed in response to atherogenic risk reduction by lifestyle intervention and that the magnitude of improvement correlates to increases in plasma HDL levels. Thus, serial 18F-FDG PET/CT may be useful for monitoring improvements in the inflammatory component of atherosclerotic lesions in response to risk modification.     

重视乳腺疾病的影像学诊断

随着国内乳腺癌发病率的不断上升，乳腺疾病的影像诊断日益引起人们的兴趣和关注。近20余年来，由于钼靶X线机、B超（高频探头）及MRI在国内已逐渐普及，使乳腺疾病诊断工作从初期只有少数几家医院开展，发展到在全国得以普及，且研究逐年深化，与国际先进水平的差距亦逐年缩小。     

耐药相关蛋白P-gp、GST-π、TopoⅡ在原发性肝癌中的表达及其临床意义

目的探讨原发性肝癌组织中的P-糖蛋白（P—glycoprotein，P—gP）、谷胱甘肽-S转移酶-π（glutahione-S—transferase-π，GST-π）、DNA拓扑异构酶Ⅱ（DNA—topoismerase，TopoⅡ）耐药基因的表达及其临床意义。方法采用免疫组化方法检测35例肝癌组织、20例癌旁和10例肝硬化组织中P—gP、GST-π、TopoⅡ的表达，并对其组织病理指标及3年生存率进行综合分析。结果①35例肝癌中的P—gp、GST-π、TopoⅡ的阳性表达率分别为85．7％、71．4％、31．4％。②肝癌组织中P—gp、GST-π表达显著高于癌旁组织及肝硬化组织。③P—gp＋GST-π＋TopoⅡ阳性表达率为17．1％，P—gp＋GST-π、P—gp＋TopoⅡ和GST-π＋TopoⅡ阳性率分别为60％、14．3％、2．8％，其中P—gP＋GST-π和GST-π＋TopoⅡ的阳性表达具有相关性（P〈0．01）。④TopoⅡ表达阳性者的3年生存率低于阴性者。结论①原发性肝癌多药耐药与其P—gp、GST-π、TopoⅡ表达有关。②对肝癌患者化疗前进行耐药基因检测，对患者化疗用药具有指导意义，有助于联合用药的合理选择，提高疗效及延长患者生存期。     

Inhibition of bone healing by pamidronate in calvarial bony defects.

OBJECTIVE: Pamidronate has been studied as a therapeutic drug for various osteopenic diseases. However, avascular osteonecrosis in the jawbone has been recently reported in patients receiving pamidronate. The objective of this study was to examine the effect of pamidronate on bone regeneration in a controlled animal model. MATERIALS AND METHODS: To determine the effect of parmidronate on bone healing in a local bony defect area, a rabbit calvarial bony defect model was used and poly L-lactide-co-glycolide (PLGA) used as a drug carrier material. Four defect groups were made in each rabbit calvaria and the defects were treated as follows: untreated bony defect (group 1), PLGA only (group 2), 2 mg of pamidronate with PLGA (group 3), and 3 mg of pamidronate with PLGA (group 4). Bone healing was evaluated by radiography and histology at 1, 2, 4, 6, and 8 weeks after surgery. RESULTS: In radiographic analysis, radiopacity was lower in pamidronate groups than non-operated rabbit calvarial bone at all observation points (P < .05). In histological analysis, the initial bone formation at 1 week was not different among groups, but it was much lower in the pamidronate groups than in the control or PLGA group after 2 weeks. Newly formed bone at 1 week underwent avascular necrosis after 2 weeks in both pamidronate groups. Avascular necrosis was not observed until 8 weeks in both topically applied pamidronate groups. CONCLUSION: Collectively, pamidronate inhibits bone healing in rabbit calvarial bony defect and it may explain the avascular necrosis of the jaws in patients receiving pamidronate.     

邻近皮瓣修复面部皮肤缺损

目的 探讨邻近皮瓣修复面部皮肤缺损的应用效果。方法 162例面部病变切除后皮肤缺损患者，其中先天性色素痣63例，基底细胞癌28例，鳞状细胞癌6例，其他皮肤病变65例。均采用邻近皮瓣即时修复，其中菱形皮瓣57例、双叶皮瓣8例，A-T皮瓣23例、V-Y皮瓣13例、Z成形术23例、推进皮瓣27例、鼻状皮瓣11例。结果 162例皮瓣存活良好，手术切口1期愈合，存活后皮瓣颜色与邻近部位无明显差异，术后无眼睑、眉毛、鼻梁及口角牵扯歪钭，术后3个月切口不显露。结论 邻近皮瓣是修复面部较大皮肤缺损的良好方法，手术外观效果好。     

胰岛素抑制突变亨廷顿蛋白的聚积和毒性

目的:探讨胰岛素对细胞内突变亨廷顿蛋白(Huntingtin,htt)聚集物形成及其细胞毒性的影响.方法:利用脂质体转染法在培养的Hela细胞和HEK293细胞瞬时或稳定转染编码正常或突变htt的氨基末端片段的cDNA,检测不同浓度胰岛素刺激对细胞内突变htt聚集物形成以及细胞活力的影响.结果:在瞬时转染的Hela细胞和稳定转染的HEK293细胞中,含20个谷氨酰胺重复序列(20Q)的正常htt氨基末端片段弥散分布在胞浆内,而含150个谷氨酰胺重复序列(150Q)的突变htt氨基末端片段在多数细胞胞浆或核内形成聚集物.150Q的Hela和HEK293细胞经一定浓度的胰岛素刺激后聚集物的形成显著减少,细胞活力也明显提高.而胰岛素的刺激对20Q的细胞内正常htt的表达以及细胞活力无明显影响.结论:胰岛素能有效抑制细胞内突变htt聚集物的形成及其细胞毒性.     

Treatment failure in intracranial primary germinomas

Object A radiation dose of 40–50 Gy is able to produce a cure rate of more than 90% in intracranial pure germinoma. However, many attempts have been made to reduce the dose and volume of radiation without compromising the disease control rate because of the toxicity of irradiation. This retrospective study is intended to provide the physician with an appropriate therapeutic strategy. Materials and methods We reviewed a series of 10 recurrent germinomas among 117 germinomas diagnosed histologically or clinically between 1979 and 2002. These patients involved underwent three different treatment modalities; radiation alone (N = 71), chemotherapy alone (N = 9), and combined therapy (N = 37). The 10-year overall and relapse-free survival rates were 97 and 93% in the radiation alone group, 89 and 67% in the chemotherapy alone group, and 92 and 92% in the combined therapy group, respectively. As expected, both radiation therapy and combined therapy were effective in controlling the disease. Tumor recurrence was closely related to the volume of radiation but not to the dose of radiation. If the tumor bed and craniospinal axis were fully covered, the radiation dose might be reduced. Chemotherapy alone showed earlier recurrence and a higher tumor recurrence rate. In the case of combined therapy, chemotherapy was useful in reducing the radiation dose but revealed some toxicity (death of two patients). Conclusions The investigation of a possible further dose reduction seems worthwhile. Radiation therapy alone with a dose of less than 40 Gy should be compared with ongoing chemotherapeutic protocols combined with low-dose irradiation.     

Effect of nuclear factor-κB p65 ASOND on I typ collagen expression and rat hepatic stellate cells proliferation

Objective Sstudy effect of nuclear factor-κB ASOND on I type collagen expression and rat hepatic stellate cells(HSC)proliferation.Methods Rat HSCs were separated by affusing and digestingof Ⅳ type collagenenzyme and density acentric method.Lipid-mediated NF-κB p65 ASOND(0.001,0.01,0.1,1μmol/L)Was transferred into rat HSCs.Toxicity of HSCs caused by NF-κB p65 ASOND and activity of LDH were determined by trypan blue staining.Proliferation affection of transferring NF-κB p65 ASOND into HSCs was determined by MTT.In different concentration NF-κB p65 ASOND.expression of Ⅰ type collagen stimulated by 1mg/L TNF-αwas determined by RT-PCR and ELISA.Results After transfection of NF-κB p65 ASODN,expression of NF-κB protein in HSCs was decreasing.Toxicity experiment indicated that NF-κB p65 ASOND of different concentration(0.001,0.01,0.1 and 1.0 μmol/L)had no effect on HSCs livability and LDH activity(P<0.05).Four different concentration NF-κ B p65 ASOND could restrain HSCs proliferation stimulated by 1 mg/L TNF-α.The expression of I type collagen and mRNA stimulated by 1mg/LTNF-αwas increased,and had a positive correlation with concentration(P>0.05).Conclusion NF-κB p65 ASOND may depress NF-κB activity to restrain HSCs proliferation and Ⅰ type collagen expression,and reduce extracellular matrix.     

3种钾通道在哮喘豚鼠气道高反应中的作用

目的：探讨钙激活钾通道（KCa）、延迟整流型钾通道（Kdr）和ATP敏感型钾通道（KATP）在哮喘豚鼠气道高反应中的作用。 方法： 采用离体气管环张力实验，观察加入特异性钾通道阻断剂后，与不加阻断剂相比气管环对组胺反应的量效曲线的差异。 结果： （１）加入KCa阻断剂TEA后，对照组气管环对组胺的反应变化不显著，而哮喘组气管环对10-4mol/L、10-3mol/L组胺的收缩反应均显著低于不加TEA的气管环(P<0.01)，量效曲线明显下移；（2）加入Kdr阻断剂4-AP后，对照组气管环对10-3mol/L组胺的最大收缩反应明显下降(P<0.05)，组胺的量效曲线下移，哮喘组气管环对10-4mol/L、10-3mol/L组胺的收缩反应均低于不加4-AP的气管环(P<0.01)，且下降程度较对照组大（P<0.05），量效曲线明显下移；（3）加入KATP阻断剂glibenclamide后，对照组和哮喘组气管环对组胺的量效曲线与不加glibenclamide的气管环相比变化均无明显差异。 结论： 在豚鼠哮喘模型中，KCa和Kdr活性的降低在气道高反应的发生中起介导作用，KATP作用不明显。